147 related articles for article (PubMed ID: 29502359)
21. Comparison of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mouse, a murine homolog of X-linked hypophosphatemia.
Leifheit-Nestler M; Kucka J; Yoshizawa E; Behets G; D'Haese P; Bergen C; Meier M; Fischer DC; Haffner D
Bone; 2017 Oct; 103():224-232. PubMed ID: 28728941
[TBL] [Abstract][Full Text] [Related]
22. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.
Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S
J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.
Martin A; David V; Li H; Dai B; Feng JQ; Quarles LD
Mol Endocrinol; 2012 Nov; 26(11):1883-95. PubMed ID: 22930691
[TBL] [Abstract][Full Text] [Related]
24. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.
Martin A; Liu S; David V; Li H; Karydis A; Feng JQ; Quarles LD
FASEB J; 2011 Aug; 25(8):2551-62. PubMed ID: 21507898
[TBL] [Abstract][Full Text] [Related]
25. Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin.
Rowe PS; Matsumoto N; Jo OD; Shih RN; Oconnor J; Roudier MP; Bain S; Liu S; Harrison J; Yanagawa N
Bone; 2006 Oct; 39(4):773-86. PubMed ID: 16762607
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption.
Johnson K; Levine K; Sergi J; Chamoun J; Roach R; Vekich J; Favis M; Horn M; Cao X; Miller B; Snyder W; Aivazian D; Reagan W; Berryman E; Colangelo J; Markiewicz V; Bagi CM; Brown TP; Coyle A; Mohammadi M; Magram J
J Bone Miner Res; 2017 Oct; 32(10):2062-2073. PubMed ID: 28600887
[TBL] [Abstract][Full Text] [Related]
27. Soluble Klotho causes hypomineralization in Klotho-deficient mice.
Minamizaki T; Konishi Y; Sakurai K; Yoshioka H; Aubin JE; Kozai K; Yoshiko Y
J Endocrinol; 2018 Jun; 237(3):285-300. PubMed ID: 29632215
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D sterols increase FGF23 expression by stimulating osteoblast and osteocyte maturation in CKD bone.
Pereira RC; Salusky IB; Bowen RE; Freymiller EG; Wesseling-Perry K
Bone; 2019 Oct; 127():626-634. PubMed ID: 31377240
[TBL] [Abstract][Full Text] [Related]
29. Mineralized tissues in hypophosphatemic rickets.
Robinson ME; AlQuorain H; Murshed M; Rauch F
Pediatr Nephrol; 2020 Oct; 35(10):1843-1854. PubMed ID: 31392510
[TBL] [Abstract][Full Text] [Related]
30. Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult Hyp mice.
Carpenter KA; Davison R; Shakthivel S; Anderson KD; Ko FC; Ross RD
Bone; 2022 Jan; 154():116201. PubMed ID: 34537437
[TBL] [Abstract][Full Text] [Related]
31. Conditional Deletion of Murine Fgf23: Interruption of the Normal Skeletal Responses to Phosphate Challenge and Rescue of Genetic Hypophosphatemia.
Clinkenbeard EL; Cass TA; Ni P; Hum JM; Bellido T; Allen MR; White KE
J Bone Miner Res; 2016 Jun; 31(6):1247-57. PubMed ID: 26792657
[TBL] [Abstract][Full Text] [Related]
32. Osteocyte-specific deletion of Fgfr1 suppresses FGF23.
Xiao Z; Huang J; Cao L; Liang Y; Han X; Quarles LD
PLoS One; 2014; 9(8):e104154. PubMed ID: 25089825
[TBL] [Abstract][Full Text] [Related]
33. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization.
Liu S; Gupta A; Quarles LD
Curr Opin Nephrol Hypertens; 2007 Jul; 16(4):329-35. PubMed ID: 17565275
[TBL] [Abstract][Full Text] [Related]
34. Pathogenic role of Fgf23 in Dmp1-null mice.
Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
[TBL] [Abstract][Full Text] [Related]
35. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.
Larsson T; Marsell R; Schipani E; Ohlsson C; Ljunggren O; Tenenhouse HS; Jüppner H; Jonsson KB
Endocrinology; 2004 Jul; 145(7):3087-94. PubMed ID: 14988389
[TBL] [Abstract][Full Text] [Related]
36. Dysregulated gene expression in the primary osteoblasts and osteocytes isolated from hypophosphatemic Hyp mice.
Miyagawa K; Yamazaki M; Kawai M; Nishino J; Koshimizu T; Ohata Y; Tachikawa K; Mikuni-Takagaki Y; Kogo M; Ozono K; Michigami T
PLoS One; 2014; 9(4):e93840. PubMed ID: 24710520
[TBL] [Abstract][Full Text] [Related]
37. Genetic Ablation of Osteopontin in Osteomalacic Hyp Mice Partially Rescues the Deficient Mineralization Without Correcting Hypophosphatemia.
Hoac B; Østergaard M; Wittig NK; Boukpessi T; Buss DJ; Chaussain C; Birkedal H; Murshed M; McKee MD
J Bone Miner Res; 2020 Oct; 35(10):2032-2048. PubMed ID: 32501585
[TBL] [Abstract][Full Text] [Related]
38. Novel regulators of Fgf23 expression and mineralization in Hyp bone.
Liu S; Tang W; Fang J; Ren J; Li H; Xiao Z; Quarles LD
Mol Endocrinol; 2009 Sep; 23(9):1505-18. PubMed ID: 19556340
[TBL] [Abstract][Full Text] [Related]
39. FGF and ERK signaling coordinately regulate mineralization-related genes and play essential roles in osteocyte differentiation.
Kyono A; Avishai N; Ouyang Z; Landreth GE; Murakami S
J Bone Miner Metab; 2012 Jan; 30(1):19-30. PubMed ID: 21678127
[TBL] [Abstract][Full Text] [Related]
40. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
